Compare NVX & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVX | KALA |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | Australia | United States |
| Employees | 192 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.3M | 172.0M |
| IPO Year | N/A | 2017 |
| Metric | NVX | KALA |
|---|---|---|
| Price | $0.62 | $2.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 273.1K | ★ 2.4M |
| Earning Date | 04-30-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3,904.19 | N/A |
| Revenue Next Year | $91.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.07 |
| 52 Week High | $3.86 | $20.58 |
| Indicator | NVX | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 69.05 |
| Support Level | $0.62 | $0.32 |
| Resistance Level | $0.76 | $3.96 |
| Average True Range (ATR) | 0.04 | 0.28 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 23.83 | 66.65 |
NOVONIX Ltd is a battery technology company developing and scaling materials and equipment critical to the lithium-ion battery supply chain. The company has three operating segments: Battery Materials: It develops and manufactures battery anode materials, ii) Battery Technology: It develops and manufactures battery cell testing equipment, performs consulting services and carries out research and development in battery development, and Graphite Exploration: It manages the maintenance and future development of Mount Dromedary natural graphite deposit. The majority of the company's revenue is derived from the Battery Technology segment. Geographically, the maximum revenue is derived from North America, followed by Asia, and Europe.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.